Revance is proud to introduce the latest addition to its prestige clinical skincare brand, StriVectin, with the launch of the new Barrier Restore+ Collection, debuting with two innovative products: ...

With a new cosmetic dermal filler that works twice as long as AbbVie’s Botox, Nashville, Tennessee, company Revance thought it could capture what it termed the “prestige market.” That, of course, came ...

"Hypochlorous Acid is well recognized in dermatology for its ability to reduce bacteria and calm redness without disrupting the skin barrier," said Marisa Garshick, MD. "This mist is a great option ...

JOHNSON CITY & NASHVILLE, Tenn., January 21, 2025--(BUSINESS WIRE)--Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it faces a new obstacle: a patent ...

Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...

Just prior to the recent share price spike, Revance filed anS3 registration statementallowing the sale of 8.4 million shares by restricted major shareholders. When I first heard about Revance ...

Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...

NASHVILLE, Tenn., Jan. 27, 2026 /PRNewswire/ -- Revance, a fast-growing global leader in aesthetics and skincare, today announced its participation in the 2026 International Master Course on Aging ...

(Reuters) -Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought by privately held Crown Laboratories in a deal valued at $924 million, including debt, seeking scale to compete ...

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and ...